- Valion Bio has opened its wholly owned manufacturing subsidiary, Velocity Bioworks, in San Antonio to support Entolimod production and CDMO operations.
- The facility supports domestic biologics manufacturing, including programs tied to acute radiation syndrome and oncology supportive care.
Valion Bio, Inc. has officially opened Velocity Bioworks, its wholly owned biomanufacturing subsidiary, at the VelocityTX innovation campus in San Antonio, Texas. The company said the facility supports its vertically integrated manufacturing strategy and expands its domestic biologics production capabilities.
According to Valion Bio, Velocity Bioworks will support manufacturing of Entolimod™, the company’s clinical-stage immunotherapeutic candidate being developed for acute radiation syndrome, oncology supportive care, and longevity-related indications. The facility also positions the company to operate as a contract development and manufacturing organization supporting third-party biologics programs.
The company stated that Velocity Bioworks currently employs approximately 45 scientists, engineers, and operators in San Antonio and has completed technology transfer activities for Entolimod manufacturing, including scale-up work to support GMP production. The site will support manufacturing programs tied to collaborations with U.S. government agencies including BARDA and NIAID for potential inclusion of Entolimod in the Strategic National Stockpile.
Valion Bio said Entolimod is a Toll-like receptor 5 agonist being evaluated both as a medical countermeasure for acute radiation syndrome and as a supportive care therapy for chemotherapy-induced neutropenia. The company noted that the manufacturing facility was established in San Antonio because of the region’s life sciences infrastructure, military medical research presence, and logistics network.
“Through Velocity Bioworks’ operations in San Antonio, we control the manufacturing of Entolimod end-to-end — and we are positioned to deliver for cancer patients, for the Strategic National Stockpile, and for the broader biologics industry as a third-party CDMO partner.”
Michael K. Handley, Chief Executive Officer of Valion Bio
